A detailed history of M&T Bank Corp transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 113,907 shares of CCCC stock, worth $461,323. This represents 0.0% of its overall portfolio holdings.

Number of Shares
113,907
Previous 113,907 -0.0%
Holding current value
$461,323
Previous $649,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$4.43 - $7.38 $81,804 - $136,279
18,466 Added 19.35%
113,907 $649,000
Q2 2024

Jul 31, 2024

BUY
$4.05 - $8.1 $43,055 - $86,111
10,631 Added 12.54%
95,441 $440,000
Q1 2024

May 07, 2024

SELL
$5.3 - $11.0 $285,023 - $591,558
-53,778 Reduced 38.8%
84,810 $692,000
Q4 2023

Feb 06, 2024

SELL
$1.18 - $6.03 $1,689 - $8,634
-1,432 Reduced 1.02%
138,588 $783,000
Q3 2023

Nov 02, 2023

BUY
$1.81 - $3.89 $253,436 - $544,677
140,020 New
140,020 $260,000
Q1 2023

May 11, 2023

BUY
$3.1 - $9.02 $33,194 - $96,586
10,708 Added 17.47%
72,000 $226,000
Q4 2022

Feb 13, 2023

SELL
$5.42 - $10.24 $106,790 - $201,758
-19,703 Reduced 38.52%
31,447 $185,000
Q4 2022

Feb 13, 2023

BUY
$5.42 - $10.24 $161,759 - $305,612
29,845 Added 94.91%
61,292 $361,000
Q3 2022

Nov 14, 2022

SELL
$8.03 - $12.77 $87,077 - $138,477
-10,844 Reduced 17.49%
51,150 $448,000
Q2 2022

Aug 05, 2022

BUY
$5.06 - $26.46 $225,908 - $1.18 Million
44,646 Added 257.36%
61,994 $468,000
Q1 2022

May 09, 2022

BUY
$19.99 - $33.23 $198,780 - $330,439
9,944 Added 134.31%
17,348 $420,000
Q4 2021

Feb 07, 2022

BUY
$29.39 - $46.86 $42,527 - $67,806
1,447 Added 24.29%
7,404 $238,000
Q3 2021

Oct 28, 2021

SELL
$35.91 - $50.5 $1,472 - $2,070
-41 Reduced 0.68%
5,957 $266,000
Q2 2021

Aug 13, 2021

BUY
$30.39 - $42.18 $182,279 - $252,995
5,998 New
5,998 $227,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $198M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track M&T Bank Corp Portfolio

Follow M&T Bank Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.